Vosoritide for Short Stature in Turner Syndrome
This study is testing a medication called vosoritide for girls with Turner Syndrome (a genetic condition affecting females, causing short stature) and short stature. Researchers want to see if vosoritide can help these girls grow taller. Vosoritide works by targeting growth plates in bones to increase cell growth. This study is for girls aged 3 to 11 years old who have Turner Syndrome and short stature, and who either haven't tried growth hormone (GH) therapy or haven't responded well to it. The main goals are to check for any side effects and to measure how much the girls grow over 12 months. The study plans to enroll 20 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 20 female participants.
- What's involved
- Participants will receive daily injections of vosoritide for 12 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main measurements for the study will be taken at 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Vosoritide for Short Stature in Turner Syndrome
At a glance
Conditions
NCT05849389
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Children's National Hospital
Washington D.C., District of Columbiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Roopa Kanakatti Shankar, MBBS, MS · PRINCIPAL_INVESTIGATOR · Children's National Research Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of treatment-emergent adverse events12 months
Number of treatment-emergent adverse events or serious adverse events per study participant
- Change from baseline in annualized growth velocity12 months
To evaluate the change from baseline in annualized growth velocity after 12 months of daily subcutaneous injections of vosoritide
- Change from baseline in age-sex standardized height standard deviation score12 months
To evaluate the change from baseline in age-sex standardized height standard deviation score (SDS) after 12 months of daily subcutaneous injections of vosoritide